The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Unpredictable and politically driven regulatory approaches cultivate an environment of enormous uncertainty for vaccine ...

Moderna MRNA announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a ...

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...

The FDA is implementing stricter guidance for the approval of COVID-19 vaccines, according to a paper published in The New England Journal of Medicine.

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...

Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...

The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...

The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it ...

After years of strategic pivots and battling the bureaucracy, Novavax (NASDAQ:NVAX) has finally secured full FDA approval of their COVID-19 vaccine, NUVAXOVID. Not only does the BLA approval ...

The FDA has approved the Novavax Covid-19 vaccine, but with restrictions, limiting its use to older adults and those over 12 with high-risk medical conditions. This decision follows debates among ...

Jacobs, President and Chief Executive Officer, Novavax. Along with the approval, the FDA also requested Novavax conduct a phase 4 randomized, double-blinded, placebo-controlled efficacy and safety ...